Nidan Laboratories & Healthcare Ltd
Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services[1]
- Market Cap ₹ 28.0 Cr.
- Current Price ₹ 20.2
- High / Low ₹ 31.6 / 16.0
- Stock P/E 12.1
- Book Value ₹ 50.1
- Dividend Yield 0.00 %
- ROCE 6.17 %
- ROE 2.92 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.40 times its book value
- Debtor days have improved from 39.1 to 18.9 days.
Cons
- The company has delivered a poor sales growth of 2.76% over past five years.
- Company has a low return on equity of 2.60% over last 3 years.
- Earnings include an other income of Rs.2.39 Cr.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 20.07 | 21.41 | 20.38 | 29.66 | 24.27 | 24.18 | 24.53 | 27.11 | |
| 12.23 | 13.78 | 11.49 | 20.25 | 17.47 | 17.74 | 19.47 | 22.11 | |
| Operating Profit | 7.84 | 7.63 | 8.89 | 9.41 | 6.80 | 6.44 | 5.06 | 5.00 |
| OPM % | 39.06% | 35.64% | 43.62% | 31.73% | 28.02% | 26.63% | 20.63% | 18.44% |
| 0.37 | 0.01 | 1.06 | 0.40 | 3.33 | -3.76 | 2.25 | 2.39 | |
| Interest | 4.75 | 3.74 | 3.46 | 2.66 | 2.22 | 2.18 | 2.14 | 2.14 |
| Depreciation | 3.24 | 3.19 | 3.18 | 2.63 | 3.10 | 2.87 | 2.41 | 1.99 |
| Profit before tax | 0.22 | 0.71 | 3.31 | 4.52 | 4.81 | -2.37 | 2.76 | 3.26 |
| Tax % | 0.00% | 0.00% | 30.21% | 41.15% | 26.40% | 36.29% | 28.26% | |
| 0.22 | 0.71 | 2.30 | 2.66 | 3.54 | -3.23 | 1.98 | 2.31 | |
| EPS in Rs | 0.22 | 0.72 | 2.32 | 1.91 | 2.55 | -2.32 | 1.42 | 1.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -6% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | -7% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -28% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.90 | 9.90 | 9.90 | 13.90 | 13.90 | 13.90 | 13.90 | 13.90 |
| Reserves | 0.41 | 1.13 | 3.43 | 52.00 | 55.54 | 52.31 | 54.28 | 55.72 |
| 32.16 | 34.35 | 38.04 | 19.29 | 10.93 | 12.44 | 11.11 | 12.50 | |
| 0.58 | -0.17 | 2.37 | 3.29 | 4.03 | 3.90 | 3.65 | 3.64 | |
| Total Liabilities | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 85.76 |
| 23.28 | 20.10 | 19.92 | 20.46 | 21.39 | 17.95 | 16.33 | 15.50 | |
| CWIP | 0.00 | 0.00 | 0.23 | 3.81 | 0.00 | 0.04 | 0.15 | 0.15 |
| Investments | 0.53 | 0.53 | 0.27 | 0.00 | 0.00 | 0.00 | 20.00 | 20.00 |
| 19.24 | 24.58 | 33.32 | 64.21 | 63.01 | 64.56 | 46.46 | 50.11 | |
| Total Assets | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 85.76 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 8.95 | 4.62 | 4.35 | 7.83 | 10.97 | 5.52 | 2.28 | |
| 1.00 | -0.01 | -3.22 | -35.74 | -0.29 | -10.60 | -0.22 | |
| -5.81 | -1.56 | -1.22 | 28.72 | -10.37 | -0.49 | -3.01 | |
| Net Cash Flow | 4.14 | 3.05 | -0.10 | 0.80 | 0.32 | -5.57 | -0.95 |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 102.03 | 92.57 | 97.25 | 65.96 | 90.69 | 7.85 | 18.90 |
| Inventory Days | 16.98 | 12.88 | 18.17 | 25.99 | |||
| Days Payable | 116.72 | -25.76 | 213.05 | 135.84 | |||
| Cash Conversion Cycle | 2.29 | 131.22 | -97.64 | -43.89 | 90.69 | 7.85 | 18.90 |
| Working Capital Days | 256.25 | 291.69 | -189.31 | 54.52 | 43.46 | 243.18 | -13.39 |
| ROCE % | 10.13% | 13.99% | 10.09% | 8.17% | 7.95% | 6.17% |
Documents
Announcements
-
Copy of Newspaper Publication
12 November 2025 - H1 Sep 30, 2025: Total income Rs1,312.10L; PAT after tax Rs143.37L; Board approved Nov 10.
-
Outcome of Board Meeting
10 November 2025 - Board approved unaudited H1 results and accepted limited review for half year ended 30 September 2025.
-
Outcome of Board Meeting
10 November 2025 - Unaudited half-year financial results for period ended Sep 30, 2025 approved; limited review enclosed.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
13 October 2025 - SEBI Reg 74(5) certificate for quarter ended 30 Sep 2025 confirming dematerialisation.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
7 October 2025 - Nidan: Reg.27 not applicable for quarter ended 30 Sep 2025; SME listing exempt under Reg.15.
Business Overview:[1]
NLHL is a Healthcare Division of Nidan Group. It operates 35 diagnostic centers across Greater Mumbai under the Nidan Diagnostics brand. Services include CT scan, MRI, Ultrasound, 2D Echo, ECG, and more.